NCT00726726 Drug Interaction Study With a Potential Alzheimer's Disease Compound Status COMPLETED Phase PHASE1
NCT00725400 Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma Status WITHDRAWN Phase PHASE2
NCT00724334 A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis Status COMPLETED Phase PHASE1/PHASE2
NCT00722358 A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects Status COMPLETED Phase PHASE2
NCT00719225 A Belatacept Compassionate Use Study for Patients With a Kidney Transplant Status NO_LONGER_AVAILABLE Phase N/A
NCT00716456 Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib Status COMPLETED Phase PHASE1/PHASE2
NCT00716352 Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes Status COMPLETED Phase NA
NCT00714961 Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction Status COMPLETED Phase PHASE3
NCT00707590 Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM) Status TERMINATED Phase PHASE1
NCT00706641 Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder Status COMPLETED Phase NA
NCT00705367 Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg Status COMPLETED Phase PHASE1
NCT00704106 Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders Status COMPLETED Phase N/A
NCT00703469 A Study of MDX-1106 to Treat Patients With Hepatitis C Infection Status COMPLETED Phase PHASE1
NCT00699790 Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance Status COMPLETED Phase PHASE2
NCT00698932 Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control Status COMPLETED Phase PHASE3
NCT00696072 Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic Status COMPLETED Phase PHASE2